Dose de-escalation improved patient-reported outcomes in early p16-positive oropharyngeal cancer
Reducing radiotherapy from 70 Gy to 60 Gy was associated with better one-year swallowing outcomes and lower acute toxicity in selected patients.
Reducing radiotherapy from 70 Gy to 60 Gy was associated with better one-year swallowing outcomes and lower acute toxicity in selected patients.
In mice, ultrahigh dose-rate X-rays caused less early testicular damage than conventional irradiation, with protection linked to ferroptosis suppression.
Risk-adapted esophagus-sparing radiotherapy maintained target coverage, with grade 3 esophagitis in only 1.25% of high-risk patients.
Radioresistant tumors showed impaired ferroptosis and regulatory T-cell accumulation, while sorafenib enhanced the response to irradiation in mice.
FLASH radiotherapy preserved hepatic structure and metabolic homeostasis while maintaining tumor control in a preclinical breast cancer model.
Circulating lymphocyte counts remained stable during brain radiotherapy without concurrent chemotherapy, consistent with low estimated blood and cervical lymph-node dose